Literature DB >> 29967089

PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii.

Samantha D Splitt1, Scott P Souza1, Kristen M Valentine1, Brayan E Castellanos1, Andrew B Curd1, Katrina K Hoyer1, Kirk D C Jensen2.   

Abstract

T cell exhaustion is a state of hyporesponsiveness that develops during many chronic infections and cancer. Neutralization of inhibitory receptors, or "checkpoint blockade," can reverse T cell exhaustion and lead to beneficial prognoses in experimental and clinical settings. Whether checkpoint blockade can resolve lethal acute infections is less understood but may be beneficial in vaccination protocols that fail to elicit sterilizing immunity. Since a fully protective vaccine for any human parasite has yet to be developed, we explored the efficacy of checkpoint inhibitors in a mouse model of Toxoplasma gondii reinfection. Mice chronically infected with an avirulent type III strain survive reinfection with the type I RH strain but not the MAS, GUY-DOS, and GT1 parasite strains. We report here that mouse susceptibility to secondary infection correlates with the initial parasite burden and that protection against the RH strain is dependent on CD8 but not CD4 T cells in this model. When given a lethal secondary infection, CD8 and CD4 T cells upregulate several coinhibitory receptors, including PD-1, TIM-3, 4-1bb, and CTLA-4. Moreover, the gamma interferon (IFN-γ) response of CD8 but not CD4 T cells is significantly reduced during secondary infection with virulent strains, suggesting that checkpoint blockade may reduce disease severity. However, single and combination therapies targeting TIM-3, CTLA-4, and/or PD-L1 failed to reverse susceptibility to secondary infection. These results suggest that additional host responses, which are refractory to checkpoint blockade, are likely required for immunity to this pathogen.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  CD4 T cells; CD8 T cells; CTLA-4; PD-1; T cell exhaustion; TIM-3; Toxoplasma gondii; atypical strains; checkpoint blockade; vaccine

Mesh:

Substances:

Year:  2018        PMID: 29967089      PMCID: PMC6105904          DOI: 10.1128/IAI.00459-18

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  95 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Innate immunity to Toxoplasma gondii infection.

Authors:  Felix Yarovinsky
Journal:  Nat Rev Immunol       Date:  2014-02       Impact factor: 53.106

3.  Quiescence of Memory CD8(+) T Cells Is Mediated by Regulatory T Cells through Inhibitory Receptor CTLA-4.

Authors:  Vandana Kalia; Laura Anne Penny; Yevgeniy Yuzefpolskiy; Florian Martin Baumann; Surojit Sarkar
Journal:  Immunity       Date:  2015-06-16       Impact factor: 31.745

4.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

5.  Endothelial cells are a replicative niche for entry of Toxoplasma gondii to the central nervous system.

Authors:  Christoph Konradt; Norikiyo Ueno; David A Christian; Jonathan H Delong; Gretchen Harms Pritchard; Jasmin Herz; David J Bzik; Anita A Koshy; Dorian B McGavern; Melissa B Lodoen; Christopher A Hunter
Journal:  Nat Microbiol       Date:  2016-02-15       Impact factor: 17.745

6.  Differential regulation of effector- and central-memory responses to Toxoplasma gondii Infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells.

Authors:  Douglas C Wilson; Gijsbert M Grotenbreg; Kenian Liu; Yanlin Zhao; Eva-Maria Frickel; Marc-Jan Gubbels; Hidde L Ploegh; George S Yap
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

9.  PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction.

Authors:  Yan Zhang; Ying Zhou; Jingsheng Lou; Jinbao Li; Lulong Bo; Keming Zhu; Xiaojian Wan; Xiaoming Deng; Zailong Cai
Journal:  Crit Care       Date:  2010-11-30       Impact factor: 9.097

10.  B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections.

Authors:  Trupti Joshi; Susana Rodriguez; Vladimir Perovic; Ian A Cockburn; Simona Stäger
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more
  3 in total

1.  The IL-12- and IL-23-Dependent NK Cell Response Is Essential for Protective Immunity against Secondary Toxoplasma gondii Infection.

Authors:  Daria L Ivanova; Tiffany M Mundhenke; Jason P Gigley
Journal:  J Immunol       Date:  2019-10-11       Impact factor: 5.422

2.  Impact of secondary TCR engagement on the heterogeneity of pathogen-specific CD8+ T cell response during acute and chronic toxoplasmosis.

Authors:  Lindsey A Shallberg; Anthony T Phan; David A Christian; Joseph A Perry; Breanne E Haskins; Daniel P Beiting; Tajie H Harris; Anita A Koshy; Christopher A Hunter
Journal:  PLoS Pathog       Date:  2022-06-21       Impact factor: 7.464

3.  Genetic mapping reveals Nfkbid as a central regulator of humoral immunity to Toxoplasma gondii.

Authors:  Scott P Souza; Samantha D Splitt; Juan C Sànchez-Arcila; Julia A Alvarez; Jessica N Wilson; Safuwra Wizzard; Zheng Luo; Nicole Baumgarth; Kirk D C Jensen
Journal:  PLoS Pathog       Date:  2021-12-06       Impact factor: 7.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.